Patents by Inventor Leszek Kotula

Leszek Kotula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide Inhibitors of ABL Kinases
    Publication number: 20120190045
    Abstract: Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue (10) is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an Abl kinase. Further provided are methods of inhibiting an Abl kinase. Also provided are methods of treating a patient having a condition characterized by a mutant Abl kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant Abl kinase. Methods of labeling an Abl kinase are also provided. Additionally, methods of isolating an Abl kinase from a tissue are provided.
    Type: Application
    Filed: March 7, 2012
    Publication date: July 26, 2012
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Leszek Kotula, Xiaoling Xiong
  • Peptide inhibitors of ABL kinases
    Patent number: 8148320
    Abstract: Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue (10) is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an AbI kinase. Further provided are methods of inhibiting an AbI kinase. Also provided are methods of treating a patient having a condition characterized by a mutant AbI kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant AbI kinase. Methods of labeling an AbI kinase are also provided. Additionally, methods of isolating an AbI kinase from a tissue are provided.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: April 3, 2012
    Assignee: New York Blood Center, Inc.
    Inventors: Leszek Kotula, Xiaoling Xiong
  • ABI1 conditional knockout mouse
    Patent number: 8110719
    Abstract: Genetically engineered conditional knock-out mice having conditional disruption of the Abi1/Hssh3bp1 gene are disclosed along with methods of making and using same.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: February 7, 2012
    Assignee: New York Blood Center, Inc.
    Inventor: Leszek Kotula
  • PEPTIDE INHIBITORS OF ABL KINASES
    Publication number: 20100184652
    Abstract: Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue (10) is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an Abl kinase. Further provided are methods of inhibiting an Abl kinase. Also provided are methods of treating a patient having a condition characterized by a mutant AbI kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant AbI kinase. Methods of labeling an AbI kinase are also provided. Additionally, methods of isolating an Abl kinase from a tissue are provided.
    Type: Application
    Filed: November 29, 2006
    Publication date: July 22, 2010
    Inventors: Leszek Kotula, Xiaoling Xiong
  • ABI1/HSSH3BP1 CONDITIONAL KNOCKOUT MOUSE
    Publication number: 20090271883
    Abstract: Genetically engineered conditional knock-out mice having conditional disruption of the Abi1/Hssh3bp1 gene are disclosed along with methods of making and using same.
    Type: Application
    Filed: April 27, 2009
    Publication date: October 29, 2009
    Inventor: Leszek Kotula